• Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.

  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
日本語

化合物のスクリーニングおよびプロファイリングサービス

ヒト組織モデルで再現性あるデータを取得。

再現性がありスケールアップ可能でバリデートされたアッセイを使ってあなたの研究プログラムをサポートします。
MIMETAS社が確立した組織モデルを使って、再現性のある化合物に関するデータをあなたに代わって取得します。標準化されたスクリーニングのワークフローに基づきバリデートされた表現型アッセイを使って、前臨床プログラムをサポートする化合物プロファイリングサービスを実施します。

安全性スクリーニングおよびプロファイリングサービス
生体を反映した組織モデルと化合物の有害事象を導き出すことのできる我々の専門知識を活用して開発初期段階からリスクを軽減します。

薬物の送達および取込みの評価
化合物選定および薬物輸送を最適化するために、画期的な健常な膜をもつ組織モデルで薬物透過をモニタリングします。

化合物のスクリーニングおよびプロファイリングサービスにご興味のある方はコンタクトフォームまたはお電話にてお問合せ下さい。

もっと知りたい方は／コンタクト

ヒト組織および病態モデルのエキスパート

Other services

個別に対応したモデル作製とアッセイ法開発
我々はOrganoPlate®を用いて革新的なヒト組織および病態モデルを作製します。ご要望に応じて我々の研究チームがアッセイ法確立をサポートします。

創薬研究パートナーシップ
我々の研究チームと肩を組んで進めれば、あなたの創薬研究の世界が広がります。OrganoPlate®で独自のヒト病態モデル研究を共に進め、明日の治療薬を創りましょう

サービス概要

ナレッジセンター

三次元培養を導入してスピードを上げましょう。OrganoPlate®を使った研究ニーズのサポート例はこちらからご覧下さい。

ナレッジセンター

革新はすぐそこに

What customers say
'
Our exciting collaboration enables our research and early development group to apply state-of-the-art organ-on-a-chip technology in the modeling of IBD and HBV. These models have the potential to improve our understanding of disease biology and transform
The 'I' in MIMETAS
'
Tackling challenges together.
What customers say
'
"The OrganoReady Colon Caco-2, combined with the OrganoTEER, have become our gold standard in vitro model for the screening of intestinal barrier disruptors at SIAF. "
What customers say
'
The OrganoPlate Caco-2 model is for us, at Merck, the most suitable platform offering at the same time scalability, speed, robustness, ease of handling, with low compound needs.
The 'I' in MIMETAS
Chiwan Chiang
Marketing Specialist
'
A day without
laughter is a day wasted.
Read more
What customers say
'
Mimetas' tumor infiltration platform demonstrated a therapeutic effect of our compound on immune cell recruitment: we’re very excited by these proof of concept data
The 'I' in MIMETAS
Jos Joore
CEO
'
We want to
empower research on complex tissue biology.
Read more
What customers say
'
Often you have to compromise it’s either the throughput or it’s the complexity of the model. Getting both in the same platform… no other platform can do that!
The 'I' in MIMETAS
Nienke Wevers
Senior Scientist
'
Nothing ventured, nothing gained.
Read more
What customers say
'
We were able to measure cell barrier permeabilities in a lung-on-a-chip model demonstrating superior sensitivity and translatability than any other lung cell model we tried before. It was also very easy to scale up our data generation workflow.
The 'I' in MIMETAS
Henriëtte Lanz
Director of Model Development
'
It should be
mandatory to
socialize with colleagues.
Read more
What customers say
'
Organoplates opened avenues that were before considered unreachable
The 'I' in MIMETAS
Bas Trietsch
Chief Technology Officer
'
We try to help
each other
as a team.
Read more
The 'I' in MIMETAS
Jacquelien Ten Dam
Chief Financial Officer
'
It always seems impossible until it’s done.
Read more
The 'I' in MIMETAS
Paul Vulto
CEO
'
Leveraging who you are, is the key to making a difference!
Read more
The 'I' in MIMETAS
Linda Gijzen
Scientific Project Lead
'
Tackling challenges together.
Read more
The 'I' in MIMETAS
Tina Thakkar
Associate Director of Sales
'
It is not really
work if you are
having fun.
Read more
The 'I' in MIMETAS
Liis Rannamäe
Laboratory Technician
'
Can be summarized in three words - engaging, playful, and innovative.
Read more
The 'I' in MIMETAS
Mieke Doornbos
Vice President Sales & Marketing
'
Celebrate
good times.
Read more
The 'I' in MIMETAS
Frederik Schavemaker
Product Design Engineer
'
Pioneering, bringing the best solutions
for scientific
discovery.
Read more
The 'I' in Mimetas
Remko van Vught
Vice President Business Development
'
Making
a difference
together.
Read more
The 'I' in MIMETAS
Lenie van den Broek
Director Biology Discovery
'
Dynamic and innovative - each day holds a surprise.
Read more
The 'I' in Mimetas
Arnaud Nicolas
Associate Director TechCore
'
Own your flaws.
Read more
Latest Whitepaper
'
Closing the Translational Gap in Cancer Drug Discovery with Comprehensive Tumor Models
Scientist
From a top pharma
New Webinar
'
Phenotypic Disease Modeling for Immuno-Oncology: Putting Targets into Patient Context

 

 



By MIMETAS and Molecular Devices
Register here

Press Release
'
MIMETAS and Astellas Enter into Strategic Partnership on Immuno-oncology
Scientist
From a top pharma
News Article
'
First Large-scale Phenotypic Screen Using Organ-on-a-Chip

 

 



By MIMETAS and Molecular Devices
Register here

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all